Switch theme
Sign up to access all valuation multiples
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
1998
143
LTM Revenue $8.0M
LTM EBITDA -$121M
$316M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Precigen has a last 12-month revenue (LTM) of $8.0M and a last 12-month EBITDA of -$121M.
In the most recent fiscal year, Precigen achieved revenue of $3.9M and an EBITDA of -$123M.
Precigen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Precigen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.0M | XXX | $3.9M | XXX | XXX | XXX |
| Gross Profit | $3.3M | XXX | -$0.3M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | -9% | XXX | XXX | XXX |
| EBITDA | -$121M | XXX | -$123M | XXX | XXX | XXX |
| EBITDA Margin | -1516% | XXX | -3146% | XXX | XXX | XXX |
| EBIT | -$114M | XXX | -$94.7M | XXX | XXX | XXX |
| EBIT Margin | -1434% | XXX | -2413% | XXX | XXX | XXX |
| Net Profit | -$119M | XXX | -$126M | XXX | XXX | XXX |
| Net Margin | -1486% | XXX | -3216% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Precigen's stock price is $1.
Precigen has current market cap of $391M, and EV of $316M.
See Precigen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $316M | $391M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Precigen has market cap of $391M and EV of $316M.
Precigen's trades at 80.6x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Precigen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Precigen has a P/E ratio of -3.3x.
See valuation multiples for Precigen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $391M | XXX | $391M | XXX | XXX | XXX |
| EV (current) | $316M | XXX | $316M | XXX | XXX | XXX |
| EV/Revenue | 39.6x | XXX | 80.6x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 94.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | -3.6x | XXX | -4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrecigen's last 12 month revenue growth is 613%
Precigen's revenue per employee in the last FY averaged $27K, while opex per employee averaged $0.7M for the same period.
Precigen's rule of 40 is -820% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Precigen's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Precigen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 613% | XXX | 449% | XXX | XXX | XXX |
| EBITDA Margin | -1516% | XXX | -3146% | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -820% | XXX | -2533% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1352% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2404% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Precigen acquired XXX companies to date.
Last acquisition by Precigen was XXXXXXXX, XXXXX XXXXX XXXXXX . Precigen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Precigen founded? | Precigen was founded in 1998. |
| Where is Precigen headquartered? | Precigen is headquartered in United States of America. |
| How many employees does Precigen have? | As of today, Precigen has 143 employees. |
| Who is the CEO of Precigen? | Precigen's CEO is Dr. Helen Sabzevari, PhD. |
| Is Precigen publicy listed? | Yes, Precigen is a public company listed on NAS. |
| What is the stock symbol of Precigen? | Precigen trades under PGEN ticker. |
| When did Precigen go public? | Precigen went public in 2013. |
| Who are competitors of Precigen? | Similar companies to Precigen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Precigen? | Precigen's current market cap is $391M |
| What is the current revenue of Precigen? | Precigen's last 12 months revenue is $8.0M. |
| What is the current revenue growth of Precigen? | Precigen revenue growth (NTM/LTM) is 613%. |
| What is the current EV/Revenue multiple of Precigen? | Current revenue multiple of Precigen is 39.6x. |
| Is Precigen profitable? | Yes, Precigen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Precigen? | Precigen's last 12 months EBITDA is -$121M. |
| What is Precigen's EBITDA margin? | Precigen's last 12 months EBITDA margin is -1516%. |
| What is the current EV/EBITDA multiple of Precigen? | Current EBITDA multiple of Precigen is -2.6x. |
| What is the current FCF of Precigen? | Precigen's last 12 months FCF is -$86.9M. |
| What is Precigen's FCF margin? | Precigen's last 12 months FCF margin is -1089%. |
| What is the current EV/FCF multiple of Precigen? | Current FCF multiple of Precigen is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
